Yazarlar : Stephens OW, Zhang Q, Qu P, Zhou Y, Chavan S, Tian E, Williams DR, Epstein J, Barlogie B, Shaughnessy JD Jr.

Yayın : Blood.

Yayın Yılı : 2011

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22072558

Konu : Myelom

Literatür İçeriği :  

Abstract

Interleukin-6 (IL-6) signaling can be enhanced through trans-signaling by the soluble interleukin-6 receptor (sIL-6r), allowing for the pleiotropic cytokine to affect cells it would not ordinarily have an effect on. Serum levels of soluble interleukin-6 receptor (sIL-6r) can be used as an independent prognostic indicator and further stratify the GEP 70-gene low-risk group to identify an intermediate-risk group in multiple myeloma (MM). By analyzing over 600 MM patients with ELISA, genotyping, and gene expression profiling tools, we show how the combination of two independent molecular genetic events is related to synergistic increases in sIL-6r levels. We also show that the rs2228145 minor allele is related to increased expression levels of an IL-6r splice variant, which purportedly codes exclusively for a sIL-6r isoform. Together the SNP rs2228145 minor allele C and amplification of chromosome 1q21 are significantly correlated to an increase in sIL-6r levels, which are associated with lower overall survival in 70-gene low-risk disease, and aid in identification of the intermediate-risk MM group

Literatür Arşivi